M
Mona Foth
Researcher at Huntsman Cancer Institute
Publications - 19
Citations - 1364
Mona Foth is an academic researcher from Huntsman Cancer Institute. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Autophagy. The author has an hindex of 10, co-authored 16 publications receiving 977 citations. Previous affiliations of Mona Foth include University of California, Berkeley & University of Glasgow.
Papers
More filters
Journal ArticleDOI
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
Colin W. Steele,Saadia A. Karim,Joshua D.G. Leach,Peter Bailey,Rosanna Upstill-Goddard,Loveena Rishi,Mona Foth,Sheila Bryson,Karen McDaid,Zena Wilson,Catherine Anne Eberlein,Juliana Candido,Mairi Clarke,Colin Nixon,John T. Connelly,Nigel B. Jamieson,C. Ross Carter,Frances R. Balkwill,David K. Chang,T.R. Jeffry Evans,Douglas Strathdee,Andrew V. Biankin,Robert J. B. Nibbs,Simon T. Barry,Owen J. Sansom,Jennifer P. Morton +25 more
TL;DR: It is shown that CXCR2 signaling in the myeloid compartment can promote pancreatic tumorigenesis and is required for pancreatic cancer metastasis, making it an excellent therapeutic target.
Journal ArticleDOI
Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Conan G. Kinsey,Conan G. Kinsey,Soledad A. Camolotto,Amelie M. Boespflug,Amelie M. Boespflug,Katrin P. Guillen,Mona Foth,Amanda Truong,Sophia S. Schuman,Jill E. Shea,Michael T. Seipp,Jeffrey T. Yap,Jeffrey T. Yap,Lance D. Burrell,David H. Lum,Jonathan Whisenant,Jonathan Whisenant,G. Weldon Gilcrease,G. Weldon Gilcrease,Courtney C. Cavalieri,Kaitrin M. Rehbein,Stephanie L. Cutler,Kajsa E. Affolter,Kajsa E. Affolter,Alana L. Welm,Alana L. Welm,Bryan E. Welm,Bryan E. Welm,Courtney L. Scaife,Courtney L. Scaife,Eric L. Snyder,Eric L. Snyder,Martin McMahon,Martin McMahon +33 more
TL;DR: Targeted inhibition of RAF–MEK–ERK signaling induces autophagy through the LKB1–AMPK axis, creating a therapeutic vulnerability that can be exploited for treating patients with pancreatic cancer and potentially other RAS-mutant tumors.
Journal ArticleDOI
A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis
Virginie Olive,Erich Sabio,Margaux J Bennett,Caitlin S De Jong,Anne Biton,James C. McGann,Samantha K Greaney,Nicole M. Sodir,Alicia Y. Zhou,Asha Balakrishnan,Mona Foth,Micah A. Luftig,Andrei Goga,Terence P. Speed,Zhenyu Xuan,Gerard I. Evan,Ying Wan,Alex C. Minella,Lin He +18 more
TL;DR: A new paradigm is suggested whereby the unique gene structure of a polycistronic oncomir confers an intricate balance between oncogene and tumor suppressor crosstalk, as well as antagonizes the oncogenic miR-19 miRNAs.
Journal ArticleDOI
Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
Jasper Wouters,Miguel Vizoso,Anna Martínez-Cardús,F. Javier Carmona,Olivier Govaere,Teresa Laguna,Jesuchristopher Joseph,Peter Dynoodt,Claudia Aura,Mona Foth,Roy Cloots,Karin van den Hurk,Balázs Bálint,Ian G. Murphy,Enda W. McDermott,Kieran Sheahan,Karin Jirström,Björn Nodin,Girish Mallya-Udupi,Joost van den Oord,William M. Gallagher,Manel Esteller,Manel Esteller +22 more
TL;DR: A prognostic signature with potential clinical applicability is determined and PON3 DNA methylation and OVOL1 protein expression are validated as biomarkers with prognostic information independent of tumor thickness and ulceration.
Journal ArticleDOI
CXCR2 inhibition suppresses acute and chronic pancreatic inflammation
Colin W. Steele,Saadia A. Karim,Mona Foth,Loveena Rishi,Joshua D.G. Leach,Ross J Porter,Colin Nixon,T.R. Jeffry Evans,C. Ross Carter,Robert J. B. Nibbs,Owen J. Sansom,Jennifer P. Morton +11 more
TL;DR: Cxcr2 is critically involved in the development of acute and chronic pancreatitis in mice, and its inhibition or loss protects against pancreatic damage, and CXCR2 may be a viable therapeutic target in the treatment of pancreatitis.